Tokushima University / Educator and Researcher Directory --- Aoyama, Mariko

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Naoki Miyamoto, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Naoki Hino, Aya Nishisho, Yukishige Sawaka, Taeko Kawanaka, Hiromitsu Takizawa and Akira Tangoku : Absolute Lymphocyte Count Changes During Neoadjuvant Chemotherapy are Associated With Prognosis of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Patients, Clinical Breast Cancer, Vol.23, No.3, e68-e76, 2023. (Summary) Some reports have shown that absolute lymphocyte count (ALC) is associated with prognosis in breast cancer; however, the impact of ALC changes remains unclear. This study aimed to investigate the relationship between ALC changes during neoadjuvant chemotherapy for human epidermal growth factor receptor-2 (HER2)-positive breast cancer patients and disease prognosis. This retrospective cohort study January 2010 to September 2020) included patients diagnosed with HER2-positive breast cancer and treated with trastuzumab-based neoadjuvant chemotherapy. The ALC ratio was defined as the ALC value after administration of the anti-HER2 drug divided by the ALC value before administration. The optimal ALC ratio cut-off value was identified using the receiver operating characteristic curve analysis and Youden's index. The relationship between the ALC ratio and disease-free survival was assessed using the Kaplan-Meier method. Univariate and multivariate analyses were performed using the Cox proportional hazards model. Data from a total of 100 HER2-positive breast cancer patients were analyzed. The cut-off value of the ALC ratio was set as 1.142. The median follow-up period was 52.0 (range: 5.1-123.7) months. The 5-year disease-free survival rates were 88.4% and 60.9% in the high-and low-ALC ratio groups, respectively, and were significantly higher in the high-ALC ratio group (p = .0031). The ALC ratio was an independent prognostic factor in multivariate Cox proportional hazards analysis (p = .0032). HER2-positive breast cancer patients with a higher ALC ratio during trastuzumab-based neoadjuvant chemotherapy may have a better prognosis than their counterparts. (Keyword) Humans / female / Breast Neoplasms / Neoadjuvant Therapy / Retrospective Studies / Receptor, ErbB-2 / Prognosis / Trastuzumab / Disease-Free Survival / Lymphocyte Count / Antineoplastic Combined Chemotherapy Protocols (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clbc.2023.01.005 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36682907 ● Summary page in Scopus @ Elsevier: 2-s2.0-85147563272 (DOI: 10.1016/j.clbc.2023.01.005, PubMed: 36682907, Elsevier: Scopus)
2.	Mariko Aoyama, Takashi Shono, Tomohiro INUI, Naoki Miyamoto, Shin-ichi Sakamoto, Seiya Inoue, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : Abscopal effect in a patient with solitary extramedullary plasmacytoma of the thyroid: case report, Translational Cancer Research, Vol.11, No.11, 4200-4205, 2022. (Summary) The abscopal effect is a systemic antitumor response that occurs distant to the irradiation site and is induced by local irradiation. We herein describe a case of solitary extramedullary plasmacytoma (SEP) of the thyroid in which bone metastases disappeared after thyroidectomy and cervical radiotherapy (RT). A 68-year-old man with a right cervical swelling for approximately 10 years visited a hospital with left elbow pain that persisted for 5 months. He was referred to our hospital for more detailed examinations and treatment. An immobile mass of approximately 10 cm in diameter was palpable on the right side of the patient's neck. Computed tomography (CT) showed osteolytic changes in the left humerus and right scapula, and a tumor in the right lobe of the thyroid gland. The patient was diagnosed with widely invasive follicular carcinoma and multiple bone metastases and underwent total thyroidectomy. During surgery, tumor infiltration into the trachea was observed. Shaving between the tumor and trachea was performed. Based on the results of a pathological examination, the patient was diagnosed with primary extramedullary plasmacytoma of the thyroid. After surgery, external beam RT was performed on the neck, which also reduced the pain in the left elbow. Positron emission tomography (PET)-CT showed the decreased accumulation of fluorodeoxyglucose (FDG) in the left humerus and right scapula, and the amelioration of osteolytic changes on CT. SEP of the thyroid is rare, and to the best of our knowledge, this is the first case report in which the abscopal effect was observed after thyroidectomy and cervical RT. (Link to Publication Site) ● Publication site (DOI): 10.21037/tcr-22-1419 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36523308 ● Search Scopus @ Elsevier (PMID): 36523308 ● Search Scopus @ Elsevier (DOI): 10.21037/tcr-22-1419 (DOI: 10.21037/tcr-22-1419, PubMed: 36523308)
3.	Mariko Aoyama, Tomohiro Inui, Naoki Miyamoto, Shin-ichi Sakamoto, Seiya Inoue, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : A case of papillary thyroid carcinoma with renal and pulmonary metastases, Journal of Surgical Case Reports, Vol.2022, No.8, rjac366, 2022. (Summary) Distant metastases derived from papillary carcinoma are generally detected in the lungs and bones. However, renal metastasis is rare. We herein report a case of papillary thyroid carcinoma with renal and pulmonary metastases that had been initially diagnosed as primary renal carcinoma with pulmonary metastases. The lesions showed response to immune checkpoint inhibitors and tyrosine kinase inhibitor but not to radioactive iodine therapy. (Link to Publication Site) ● Publication site (DOI): 10.1093/jscr/rjac366 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35975227 ● Search Scopus @ Elsevier (PMID): 35975227 ● Search Scopus @ Elsevier (DOI): 10.1093/jscr/rjac366 (DOI: 10.1093/jscr/rjac366, PubMed: 35975227)
4.	Souichiro Sasa, Hiroaki Inoue, INUI Tomohiro, Naoki Miyamoto, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida, Tezuka Miki, Hirose Chieko, Yasuyo Saijo, Hisanori Uehara, Izumori Ayumi, Takahashi Masako, Sasa Mitsunori and Hiromitsu Takizawa : Axillary lymphangioma that developed following COVID-19 vaccination: a case report, Surgical Case Reports, Vol.8, No.1, 131, 2022. (Summary) Extensive vaccination programs are being implemented worldwide for coronavirus disease 2019 (COVID-19). With the spread of vaccination, swelling of the lymph nodes after vaccination is frequently seen. We encountered a patient who developed left axillary lymphadenoma following vaccine administration. The patient was a Japanese woman in her 80 s who had previously undergone surgery for right breast cancer. She received two injections of the Pfizer-BioNTech COVID-19 vaccine in her left arm. Approximately 3 months later, she complained of left axillary swelling, and imaging resulted in a diagnosis of left axillary lymphangioma. In accordance with the patient's wishes, we performed axillary mass resection. The pathological diagnosis was lymphangioma. Our examination findings indicated that congestion of the axillary lymph vessels might have been caused by upper-arm injections of the COVID-19 vaccine. (Link to Publication Site) ● Publication site (DOI): 10.1186/s40792-022-01488-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35798903 ● Search Scopus @ Elsevier (PMID): 35798903 ● Search Scopus @ Elsevier (DOI): 10.1186/s40792-022-01488-5 (DOI: 10.1186/s40792-022-01488-5, PubMed: 35798903)
5.	Mayumi Ikeuchi, Naoki Hino, Aya Nishisyo, Mariko Aoyama, Miyuki Kanematsu, Hiroaki Inoue, Souichiro Sasa, Tomohiro INUI, Naoki Miyamoto, Kazumasa Okumura and Hiromitsu Takizawa : Drug-induced interstitial pneumonia during perioperative chemotherapy for breast cancer, The Journal of Medical Investigation : JMI, Vol.69, No.1.2, 107-111, 2022. (Summary) Drug-induced interstitial pneumonia (DIP) that occurs during chemotherapy for breast cancer is a rare but a serious adverse event. Treatments of DIP requires interruption of breast cancer treatment, which may affect the patient's prognosis. However, there are few reports which discuss DIP during breast cancer treatments. Purpose of this report is to make clear how DIP occurred and influenced breast cancer treatment in our hospital. A total of 74 patients who started perioperative chemotherapy in Tokushima Municipal Hospital for breast cancer from January 2019 to December 2020 were evaluated for DIP. Patients' and tumors' characteristics, and regimens which caused DIP were investigated. The clinical courses of the DIP patients were also followed up. Twelve of the 74 patients developed DIP. All 12 patients had histories of cyclophosphamide administration;however, the causative drug could not be determined. Ten of the 12 patients were treated with steroids, and all the patients recovered ultimately from the interstitial pneumonia. While chemotherapy was administered in six patients after mild DIP, no relapse of pneumonia was observed. DIP during perioperative chemotherapy for breast cancer was resolved with appropriate treatment. Patients were able to resume breast cancer treatment with minimal interruption. J. Med. Invest. 69 : 107-111, February, 2022. (Keyword) breast cancer / Drug-induced interstitial pneumonia / perioperative chemotherapy (Tokushima University Institutional Repository) ● Metadata: 117020 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.69.107 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 35466130 ● CiNii @ National Institute of Informatics (CRID): 1390854882616723072 ● Search Scopus @ Elsevier (PMID): 35466130 ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.69.107 (Tokushima University Institutional Repository: 117020, DOI: 10.2152/jmi.69.107, PubMed: 35466130, CiNii: 1390854882616723072)
6.	宮本直輝, Hiroaki Inoue, INUI Tomohiro, Soichiroh Sasa, Mariko Aoyama, Hiroaki Toba, Kazumasa Okumura, Takahiro Yoshida, Hiromitsu Takizawa and Akira Tangoku : HER2陽性乳癌患者における術前化学療法開始前の総リンパ球数は予後予測の指標となり得る, Shikoku Acta Medica, Vol.77, No.3,4, 131-136, 2021. (Summary) Purpose : Several studies have shown that peripheral hematologic parameters, such as the absolute lymphocyte count(ALC)and neutrophil to lymphocyte ratio(NLR)can predict the prognosis for malignant tumor. We investigated the relation of these parameter and prognosis before neoadjuvant chemotherapy for human epidermal growth factor receptor-2(HER2)-positive breast cancer patients. Methods : From April 2009 to March 2019, 85 patients diagnosed with HER2‐positive breast cancer and treated with trastuzumab-based neoadjuvant chemotherapy were included in this retrospective cohort study. The optimal cut-off for the NLR and ALC was identified using the receiver operating characteristic(ROC)curve analysis and Youden's index. Results : The median age of patients at the start of treatment was 58．9(range 32‐81)years. The median follow-up time for HER2-positive breast cancer patients was 52．0(range:9．8‐114．3)months. In this period, 11 patients developed recurrence. The low-ALC group showed better disease free survival than the high-ALC group(p=0．0482). There was no significant difference in disease free survival between the low- and high-NLR groups. Conclusion : ALC before neoadjuvant chemotherapy may be a predictor of prolonged disease free survival in HER2‐positive breast cancer patients. (Keyword) HER2陽性乳癌 / 総リンパ球数 / 周術期化学療法 / HER2 breast cancer / neoadjuvant chemotherapy / absolute lymphocyte counts (Tokushima University Institutional Repository) ● Metadata: 116396 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050008389805360256 (Tokushima University Institutional Repository: 116396, CiNii: 1050008389805360256)
7.	Toru Sawada, Hiromitsu Takizawa, Mariko Aoyama, Naoya Kawakita, Naoki Miyamoto, Shinichi Sakamoto, Mika Takashima, Daisuke Matsumoto, Hiroaki Toba, Yukikiyo Kawakami, Mitsuteru Yoshida, Kazuya Kondo and Akira Tangoku : Diagnosis of visceral pleural invasion using confocal laser endomicroscopy during lung cancer surgery, Journal of Thoracic Disease, Vol.13, No.8, 4742-4752, 2021. (Summary) Visceral pleural invasion (VPI) in lung cancer is a significant prognostic factor; however, it is difficult to diagnose preoperatively or intraoperatively. In this study, we examined the possibility of intraoperative diagnosis of VPI using confocal laser endomicroscopy (CLE). Among patients with primary lung cancer who underwent surgery between April 2018 and August 2019, those in whom the tumor was in contact with the pleura on chest computed tomography and whose pleural changes were intraoperatively confirmed were enrolled in this study. In the 35 patients who underwent lung resection (6 cases with visceral pleural infiltration), the area where pleural change was noted was observed and a short video was recorded using CLE. Based on the video images, three evaluators determined the defect ratio (0%, 25%, 50%, 75%, and 100%) of the autofluorescence-positive structure. The area under the receiver operating characteristic curve was used to evaluate the diagnostic performance for VPI. In 15 cases (3 cases with VPI), a validation study was performed for intraoperative VPI according to the cutoff value of the defect ratio of the autofluorescence-positive structure. The areas under the receiver operating characteristic curve for the defect ratio of the autofluorescence-positive structure were 0.86-0.91 for the three readers. Using defect ratio of autofluorescence-positive structure cutoff of ≥50% as predictor of VPI, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 83.3-100.0%, 57.7-73.1%, 35.3-41.7%, 95.0-100.0%, and 75.0-78.1%, respectively, for the three readers. In the validation study, the sensitivity was 100%, the specificity was 83.3%, and the diagnostic accuracy rate was 86.7%. The diagnosis of VPI through CLE is simple, non-invasive, and has high diagnostic accuracy rates. This method may be applicable for determining surgical procedures. (Tokushima University Institutional Repository) ● Metadata: 116384 (Link to Publication Site) ● Publication site (DOI): 10.21037/jtd-21-137 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34527315 ● Summary page in Scopus @ Elsevier: 2-s2.0-85113558883 (Tokushima University Institutional Repository: 116384, DOI: 10.21037/jtd-21-137, PubMed: 34527315, Elsevier: Scopus)
8.	Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Mariko Aoyama, Naoya Kawakita, Yota Yamamoto, Yoshihito Furukita, Hiromitsu Takizawa and Akira Tangoku : Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma., General Thoracic and Cardiovascular Surgery, Vol.69, No.3, 525-533, 2021. (Summary) The prognosis of patients with esophageal squamous cell carcinoma (ESCC) has been improved by multidisciplinary therapy with chemoradiotherapy and surgery, but it remains poor. Advanced stage, malignant potential, and chemo-resistance contribute to the poor prognosis. Here, we attempted to identify predictive factors of the response to chemotherapy and the prognosis of ESCC patients. We examined 51 ESCC patients who were treated with chemotherapy followed by radical surgery, and 23 patients who were treated with chemotherapy alone. We conducted quantitative reverse transcription-polymerase chain reaction gene expression analysis using RNA extracted from 74 tumor tissue samples collected before chemotherapy and 67 tumor tissue samples collected after chemotherapy, focusing on PIK3CA, AKT-1, mTOR, 4E-BP1, p70S6K, PD-L1, and PD-L2. The proportions of patients with high expressions of AKT-1 and PD-L1 before chemotherapy were significantly higher among the non-responders than among the responders (p = 0.034, p = 0.020, respectively). Multivariate analyses revealed that high PD-L1 expression before chemotherapy was associated with poor response to chemotherapy (odds ratio 2.998; 95% CI 1.043-8.619; p = 0.042) and high p70S6K expression before chemotherapy was a poor prognostic factor (hazard ratio 2.518; 95% CI 1.058-5.988; p = 0.037). In addition, the patients with high expression of PD-L1 and PD-L2 in the tumors after chemotherapy had significantly worse survival than those with low expression of these genes (p = 0.012, p = 0.007, respectively). These results demonstrated that PD-L1 and p70S6K in the primary ESCC tissues were related to a poor response to chemotherapy and poor prognosis, respectively. (Keyword) Biomarkers, Tumor / Chemoradiotherapy / Esophageal Neoplasms / Esophageal Squamous Cell Carcinoma / Humans / Prognosis (Tokushima University Institutional Repository) ● Metadata: 115936 (Link to Publication Site) ● Publication site (DOI): 10.1007/s11748-021-01586-5 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33449265 ● Summary page in Scopus @ Elsevier: 2-s2.0-85099215910 (Tokushima University Institutional Repository: 115936, DOI: 10.1007/s11748-021-01586-5, PubMed: 33449265, Elsevier: Scopus)
9.	Hiroaki Toba, Hiromitsu Takizawa, Mariko Aoyama, Hiroaki Inoue and Akira Tangoku : Comprehensive Interventions for Building a Better Regional Cooperation for Cancer Patients, Journal of Japan Surgical Association, Vol.82, No.7, 1281-1285, 2021. (Summary) <p>Objectives : We introduce our comprehensive interventions for building a better regional cooperation for cancer patients. Methods : We have made a questionnaire survey for community physicians asking whether they can accept cancer patients and what types of medical treatments they can provide. Based on the questionnaire responses, we visualized the information, developed a new critical pathway, and improved the system in a basic hospital. Results : We first organized the information obtained from the questionnaire responses and uploaded the organized information to the basic hospital's homepage for public access. We then developed a new critical pathway for the cooperation among community physicians considering the prophylactic administration of a granulocyte-colony stimulating factor (G-CSF) formulation for treating cancer patients. This treatment was subsequently applied to four patients. Additionally, a community physician was matched with each patient by a medical social worker during the patients' hospitalization. We improved the basic hospital's simple electronic medical record system to reduce the physicians' workloads. As a result, the document creation could be completed within one minute, and so they could relate to approximately 10 times larger number of cases. Conclusions : Satisfactory cancer treatments can be provided for patients by building the better regional cooperative relationships and dividing the roles with community physicians in an earlier time.</p> (Keyword) がん患者の地域連携 / かかりつけ医 / 役割分担 / regional cooperation for cancer patients / community physician / division of roles (Link to Publication Site) ● Publication site (DOI): 10.3919/jjsa.82.1281 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390572404756753792 ● Search Scopus @ Elsevier (DOI): 10.3919/jjsa.82.1281 (DOI: 10.3919/jjsa.82.1281, CiNii: 1390572404756753792)
10.	Akira Tangoku, Hiroaki Toba, Hiroaki Inoue, Soichiroh Sasa, Kazumasa Okumura, Mariko Aoyama, INUI Tomohiro and Hiromitsu Takizawa : [ .N-1 Study]., Japanese Journal of Cancer and Chemotherapy, Vol.47, No.12, 1681-1686, 2020. (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33342983 ● Summary page in Scopus @ Elsevier: 2-s2.0-85098745716 (PubMed: 33342983, Elsevier: Scopus)
11.	Naoya Kawakita, Hiroaki Toba, Keiko Miyoshi, Shinichi Sakamoto, Daisuke Matsumoto, Mika Takashima, Mariko Aoyama, Seiya Inoue, Masami Morimoto, Takeshi Nishino, Hiromitsu Takizawa and Akira Tangoku : Bronchioalveolar stem cells derived from mouse-induced pluripotent stem cells promote airway epithelium regeneration, Stem Cell Research & Therapy, Vol.11, No.1, 430, 2020. (Summary) Bronchioalveolar stem cells (BASCs) located at the bronchioalveolar-duct junction (BADJ) are stem cells residing in alveoli and terminal bronchioles that can self-renew and differentiate into alveolar type (AT)-1 cells, AT-2 cells, club cells, and ciliated cells. Following terminal-bronchiole injury, BASCs increase in number and promote repair. However, whether BASCs can be differentiated from mouse-induced pluripotent stem cells (iPSCs) remains unreported, and the therapeutic potential of such cells is unclear. We therefore sought to differentiate BASCs from iPSCs and examine their potential for use in the treatment of epithelial injury in terminal bronchioles. BASCs were induced using a modified protocol for differentiating mouse iPSCs into AT-2 cells. Differentiated iPSCs were intratracheally transplanted into naphthalene-treated mice. The engraftment of BASCs into the BADJ and their subsequent ability to promote repair of injury to the airway epithelium were evaluated. Flow cytometric analysis revealed that BASCs represented ~ 7% of the cells obtained. Additionally, ultrastructural analysis of these iPSC-derived BASCs via transmission electron microscopy showed that the cells containing secretory granules harboured microvilli, as well as small and immature lamellar body-like structures. When the differentiated iPSCs were intratracheally transplanted in naphthalene-induced airway epithelium injury, transplanted BASCs were found to be engrafted in the BADJ epithelium and alveolar spaces for 14 days after transplantation and to maintain the BASC phenotype. Notably, repair of the terminal-bronchiole epithelium was markedly promoted after transplantation of the differentiated iPSCs. Mouse iPSCs could be differentiated in vitro into cells that display a similar phenotype to BASCs. Given that the differentiated iPSCs promoted epithelial repair in the mouse model of naphthalene-induced airway epithelium injury, this method may serve as a basis for the development of treatments for terminal-bronchiole/alveolar-region disorders. (Tokushima University Institutional Repository) ● Metadata: 115515 (Link to Publication Site) ● Publication site (DOI): 10.1186/s13287-020-01946-7 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33008488 ● Summary page in Scopus @ Elsevier: 2-s2.0-85092295153 (Tokushima University Institutional Repository: 115515, DOI: 10.1186/s13287-020-01946-7, PubMed: 33008488, Elsevier: Scopus)
12.	Soichiroh Sasa, Hiroaki Inoue, Kazumasa Okumura, Mariko Aoyama, Tomohiro INUI, Hiroaki Toba, Takahiro Yoshida, Yoshimi Bando and Akira Tangoku : A case of juvenile fibroadenoma arising from axillary accessory mammary gland, Shikoku Acta Medica, Vol.76, No.3,4, 185-190, 2020. (Summary) A case is20years old woman. She had previously noticed a mass in the left axilla. The mass grew, so she went to the hospital. Ultrasonography revealed a 71 × 51 mm well-defined tumor in the left axilla. We suspected a benign tumor but could not rule out axillary lymph node metastasis or accessory breast cancer. The findings of fine needle aspiration cytology suggested fibroadenoma or phyllodes tumor. Although we diagnosed fibroadenoma by needle biopsy, a definitive diagnosis was made by tumor resection because it is located in the axilla and large in size, and other diseases such as phyllodes tumors can be distinguished. The histopathological diagnosis of the excised specimen was juvenile fibroadenoma. We report a case of juvenile fibroadenoma arising from the axillary accessory mammary gland. (Keyword) Juvenile fibroadenoma / Axillary accessory mammary gland / Axillary tumor (Tokushima University Institutional Repository) ● Metadata: 115366 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1051975278323002880 (Tokushima University Institutional Repository: 115366, CiNii: 1051975278323002880)
13.	Masami Morimoto, Hiroaki Toba, Mariko Aoyama, Misako Nakagawa, Hirokazu Takechi, Takahiro Yoshida and Akira Tangoku : Phase 1 Dose-Escalation Study of Triweekly Nab-Paclitaxel Combined With S-1 for HER2-Negative Metastatic Breast Cancer, Clinical Breast Cancer, Vol.20, No.6, 448-453, 2020. (Summary) To evaluate the efficacy, toxicity, maximum tolerated dose, and recommended dose of triweekly nab-paclitaxel (nab-PTX) and S-1 combination chemotherapy for patients with metastatic breast cancer. This phase 1 study was conducted with a standard 3 + 3 dose escalation design. Every 3 weeks, the patients received nab-PTX at 180-260 mg/m on day 1 and S-1 at 65-80 mg/m daily on days 1 to 14. Ten HER2-negative metastatic breast cancer patients were enrolled; their median number of prior chemotherapy regimens was 3. Dose-limiting toxicity was observed in the first patient assigned to level 4; grade 4 febrile neutropenia and grade 3 neurotoxicity such as needing a wheelchair occurred. Therefore, an additional patient was not assigned to level 4. The maximum tolerated dose was considered level 4 (260 mg/m nab-PTX with 80 mg/m S-1). The recommended dose determined was level 3 (220 mg/m nab-PTX with 80 mg/m S-1). The response rate was 60.0%. The disease control rate was 70.0%. This combination chemotherapy therapy was feasible and safe for patients with HER2-negative metastatic breast cancer. (Link to Publication Site) ● Publication site (DOI): 10.1016/j.clbc.2020.07.012 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 32800494 ● Summary page in Scopus @ Elsevier: 2-s2.0-85089357765 (DOI: 10.1016/j.clbc.2020.07.012, PubMed: 32800494, Elsevier: Scopus)
14.	Hirokazu Takechi, Masami Morimoto, 田代善彦, 松山和男, 宮内隆行, 石川正志, Soichiroh Sasa, Mariko Aoyama, Seiya Inoue, Hiroaki Toba, Takahiro Yoshida and Akira Tangoku : Tolerability and efficacy of a chemotherapy regimen avoiding Anthracycline for HER2 positive elderly and poor risked breast cancer patients, Shikoku Acta Medica, Vol.76, No.1,2, 69-72, 2020. (Summary) Tolerability and efficacy of chemotherapy avoiding anthracycline regimen were examined histologically in ER negative and HER2positive elderly and poor risked breast cancer patients because of serious toxicity of Anthracycline regimen. Neo-adjuvant chemotherapy with 4 to 6 courses of Paclitaxel with Trastuzumab was given to 6 patients, Pertuzumab was added in 2 cases to obtain complete response. Adverse events were controllable, the primary treatment was completed without reducing the dose of drugs(RDI was 100%). Clinical CR rate was recognized in all 6 patients and pathological CR was proved in all of the operated5cases. (Keyword) HER2 positive breast cancer / Elderly patients / Neo-adjuvant chemotherapy / RDI / pCR rate (Tokushima University Institutional Repository) ● Metadata: 114858 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1050848249738417664 (Tokushima University Institutional Repository: 114858, CiNii: 1050848249738417664)
15.	Mariko Aoyama, Hiromitsu Takizawa, Kiyoshige Yamamoto, Tomohiro INUI, Naoki Miyamoto, Shinichi Sakamoto, Tomoko Kobayashi, Hisanori Uehara and Akira Tangoku : Effects of excitation light intensity on parathyroid autofluorescence with a novel near-infrared fluorescence imaging system : two surgical case reports, Gland Surgery, Vol.9, No.5, 1584-1589, 2020. (Tokushima University Institutional Repository) ● Metadata: 116330 (Link to Publication Site) ● Publication site (DOI): 10.21037/gs-20-386 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.21037/gs-20-386 (Tokushima University Institutional Repository: 116330, DOI: 10.21037/gs-20-386)
16.	Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Kouhei Nishioka, Keisuke Fujimoto, Mariko Aoyama, Daisuke Matsumoto, Hiromitsu Takizawa and Akira Tangoku : Safe central venous catheters for esophageal cancer treatment, The Journal of Medical Investigation : JMI, Vol.67, No.3,4, 298-303, 2020. (Summary) Introduction : Central venous catheter (CVC) use is essential for treating esophageal cancer. Peripherally inserted central catheters (PICC) are commonly used recently for improved patient comfort and safety. We compared centrally inserted central catheters (CICC) and PICC insertions and examined their safety. Methods : We retrospectively investigated complications at the catheter insertion and post-insertion for 199 patients' esophageal cancer treatment (CICC : 45, PICC : 154) from 2013 to 2018. In addition, we summarized the results of catheter tip culture. Results : No serious complications occurred at the catheter insertion in either group. The rate of complications at catheter insertion was 5.8% for PICC and 6.7% for CICC patients. Post-insertion complications were observed in 6.5% and 11.1% of patients with PICC and CICC, respectively, and this difference was not significant. The incidence of catheter-related blood stream infection (CRBSI) was significantly lower in PICC than CICC patients (0.3 vs. 1.8 / 1,000 catheter-days ; p = 0.029). Catheter-related thrombosis was observed in PICC : 0.5 and CICC : 0.6, and occlusion due to blood flow reversal was observed in PICC : 0.5 and CICC : 0.6. Conclusion : PICCs are safer and more effective than CICCs for the treatment of esophageal cancer, and reduce the incidence of CRBSI. We hope to standardize the insertion procedures, conventionalize techniques, and establish training systems. J. Med. Invest. 67 : 298-303, August, 2020. (Tokushima University Institutional Repository) ● Metadata: 115428 (Link to Publication Site) ● Publication site (DOI): 10.2152/jmi.67.298 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 33148905 ● Summary page in Scopus @ Elsevier: 2-s2.0-85095590219 (Tokushima University Institutional Repository: 115428, DOI: 10.2152/jmi.67.298, PubMed: 33148905, Elsevier: Scopus)
17.	Mariko Aoyama, Hiromitsu Takizawa, Tamaki Otani, Seiya Inoue, Naoya Kawakita, Mitsuhiro Tsuboi, Yoshimi Bando, Hisanori Uehara, Kazuya Kondo and Akira Tangoku : Noninvasive monitoring of paclitaxel and lenvatinib efficacy against anaplastic thyroid cancer in orthotopic SCID mouse models using smallanimal FDGPET/CT, Oncology Reports, Vol.44, 1709-1716, 2020. (Tokushima University Institutional Repository) ● Metadata: 115331 (Link to Publication Site) ● Publication site (DOI): 10.3892/or.2020.7720 (Link to Search Site for Scientific Articles) ● Search Scopus @ Elsevier (DOI): 10.3892/or.2020.7720 (Tokushima University Institutional Repository: 115331, DOI: 10.3892/or.2020.7720)
18.	Mitsuhiro Tsuboi, Mariko Aoyama, Hiromitsu Takizawa, Mitsuteru Yoshida, Takashi Iwata, Masashi Akaike, Hiro-omi Kanayama, Yoshihiro Tsuruo and Akira Tangoku : 内視鏡手術の教育システム, Official Journal of the Japan Association of Endocrine Surgeons and the Japanese Society of Thyroid Surgery, Vol.37, No.1, 22-26, 2020. (Link to Publication Site) ● Publication site (DOI): 10.11226/jaesjsts.37.1_22 (Link to Search Site for Scientific Articles) ● CiNii @ National Institute of Informatics (CRID): 1390848250117531136 ● Search Scopus @ Elsevier (DOI): 10.11226/jaesjsts.37.1_22 (DOI: 10.11226/jaesjsts.37.1_22, CiNii: 1390848250117531136)

Proceeding of International Conference:

1.	Seiya Inoue, Takahiro Yoshida, Masakazu Goto, Satoshi Fujiwara, INUI Tomohiro, Shin-ichi Sakamoto, Naoki Miyamoto, Mariko Aoyama, Hiroaki Toba and Hiromitsu Takizawa : The best method of the gastric tube reconstruction after esophagectomy, The International Society for Diseases of the Esophagus (VIRTUAL), Sep. 2022.

Proceeding of Domestic Conference:

1.	Seiya Inoue, Masakazu Goto, Satoshi Fujiwara, 細川暉雄, Taihei Takeuchi, 髙杉遥, Shin-ichi Sakamoto, Hiroyuki Sumitomo, Naoki Miyamoto, Atsushi Morishita, Mariko Aoyama, Naoya Kawakita, Hiroaki Toba and Hiromitsu Takizawa : 地方大学において外科医不足を補うために∼特定看護師の役割∼, 第124回日本外科学会定期学術集会, Apr. 2024.
2.	Mariko Aoyama, Seiya Inoue, 細川暉雄, Taihei Takeuchi, Shin-ichi Sakamoto, Hiroyuki Sumitomo, Naoki Miyamoto, Atsushi Morishita, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 縦隔内甲状腺・副甲状腺腫瘍に対する縦隔鏡手術の有用性, 第124回日本外科学会定期学術集会, Apr. 2024.
3.	杉本花奈乃, Hiroaki Inoue, Souichiro Sasa, Tomohiro Inui, 行重佐和香, Mariko Aoyama, Hiroaki Toba, Masakazu Goto, Yoshimi Bando and Hiromitsu Takizawa : 乳頭の硬結で発見された浸潤性小葉癌の1例, 第33回日本乳癌検診学会学術総会, Nov. 2023.
4.	行重佐和香, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Takeshi Oya, Yoshimi Bando, Masakazu Goto and Hiromitsu Takizawa : 乳腺原発神経内分泌腫瘍の1例, 第33回日本乳癌検診学会学術総会, Nov. 2023.
5.	細川暉雄, Mariko Aoyama, 竹内大平, 髙杉遥, Shin-ichi Sakamoto, Hiroyuki Sumitomo, Naoki Miyamoto, Atsushi Morishita, Seiya Inoue, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : Dynamic CTにより残存腺腫を同定した原発性副甲状腺機能亢進症の1例, 第85回日本臨床外科学会総会, Nov. 2023.
6.	Mariko Aoyama, 細川暉雄, 竹内大平, 髙杉遥, Shin-ichi Sakamoto, Hiroyuki Sumitomo, Naoki Miyamoto, Atsushi Morishita, Seiya Inoue, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 当科における中リスク甲状腺乳頭癌における治療成績に関する検討, 第85回日本臨床外科学会総会, Nov. 2023.
7.	Seiya Inoue, Masakazu Goto, Satoshi Fujiwara, 細川暉雄, 竹内大平, Hiroyuki Sumitomo, Naoki Miyamoto, Shin-ichi Sakamoto, Atsushi Morishita, Mariko Aoyama, Naoya Kawakita, Hiroaki Toba, Hiromitsu Takizawa and Yoshihiro Tsuruo : 縦隔鏡下食道切除術を安全に行うためのトレーニング, 第85回日本臨床外科学会総会, Nov. 2023.
8.	阿部祐也, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, 行重佐和香, Kazumasa Okumura, Naoki Miyamoto, Masakazu Goto, Hiroaki Toba, Takashi Kawanaka and Hiromitsu Takizawa : 顔面のしびれを契機に発見された頭蓋底骨転移に対し放射線治療が有効であった1例, 第20回日本乳癌学会中国四国地方会, Sep. 2023.
9.	細川暉雄, Tomohiro Inui, Sawaka Yukishige, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Hiroaki Toba and Hiromitsu Takizawa : 有害事象マネジメントにより術前ペムブロリズマブ投与を継続しpCRの診断を得たトリプルネガティブ乳癌の1例, 第20回日本乳癌学会中国四国地方会, Sep. 2023.
10.	Seiya Inoue, Masakazu Goto, Satoshi Fujiwara, 細川暉雄, Taihei Takeuchi, 髙杉遥, Shin-ichi Sakamoto, Hiroyuki Sumitomo, Naoki Miyamoto, Atsushi Morishita, Mariko Aoyama, Naoya Kawakita, Hiroaki Toba and Hiromitsu Takizawa : ICG胃管血流評価を意識した食道胃管吻合の取り組み, 日本蛍光ガイド手術研究会第6回学術集会, Sep. 2023.
11.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Naoki Miyamoto, Souichiro Sasa, Mariko Aoyama, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 高Ca血症のコントロールに難渋した乳癌多発骨転移の1例, 第98回中国四国外科学会総会/第28回中国四国内視鏡外科研究会, Aug. 2023.
12.	Naoki Miyamoto, Mariko Aoyama, 井﨑富由実, Taihei Takeuchi, Hiroyuki Sumitomo, Shin-ichi Sakamoto, Seiya Inoue, Satoshi Fujiwara, Naoya Kawakita, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : レンバチニブ投与により難治性気胸を発症した甲状腺未分化癌の一例, 第98回中国四国外科学会総会/第28回中国四国内視鏡外科研究会, Aug. 2023.
13.	Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, Naoki Miyamoto, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 高齢乳癌患者におけるCDK4/6阻害剤投与の検討, 第98回中国四国外科学会総会/第28回中国四国内視鏡外科研究会, Aug. 2023.
14.	Mariko Aoyama, 細川暉雄, Taihei Takeuchi, Shin-ichi Sakamoto, Hiroyuki Sumitomo, Naoki Miyamoto, Seiya Inoue, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 当科における進行・再発甲状腺癌に対するレンバチニブの使用経験と今後の治療戦略, 第98回中国四国外科学会総会/第28回中国四国内視鏡外科研究会, Aug. 2023.
15.	Seiya Inoue, Masakazu Goto, Satoshi Fujiwara, 井﨑富由実, Taihei Takeuchi, Hiroyuki Sumitomo, Shin-ichi Sakamoto, Naoki Miyamoto, Mariko Aoyama, Hiroaki Toba and Hiromitsu Takizawa : NAC後の術後補助化学療法の有用性の検討, 第77回日本食道学会学術集会, Jun. 2023.
16.	Masakazu Goto, 井﨑富由実, Sawaka Yukishige, Taihei Takeuchi, Hiroyuki Sumitomo, Mariko Aoyama, Satoshi Fujiwara, Seiya Inoue, Hiroaki Toba and Hiromitsu Takizawa : 当院における高齢者食道癌患者に対する治療と予後について, 第77回日本食道学会学術集会, Jun. 2023.
17.	Tomohiro Inui, Hiroaki Inoue, Souichiro Sasa, Kazumasa Okumura, Mariko Aoyama, Sawaka Yukishige, 井﨑富由実, Naoki Miyamoto, Hiroaki Toba, Yoshimi Bando and Hiromitsu Takizawa : 当院における肉芽腫性乳腺炎治療の検討, 第31回日本乳癌学会学術総会, Jun. 2023.
18.	Sawaka Yukishige, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura, Masakazu Goto, Hiroaki Toba, Hiromitsu Takizawa, 甫喜本憲弘 and 頼田顕辞 : 局所皮弁による再建を行った腋窩副乳癌の1例, 第31回日本乳癌学会学術総会, Jun. 2023.
19.	Mariko Aoyama, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Kazumasa Okumura, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : トリプルネガティブ乳癌におけるHER2低発現の有無による臨床病理学的所見と予後の検討, 第31回日本乳癌学会学術総会, Jun. 2023.
20.	Hiroaki Inoue, Souichiro Sasa, Kazumasa Okumura, Mariko Aoyama, Tomohiro Inui, Sawaka Yukishige, 井﨑富由実, Naoki Miyamoto, Hiroaki Toba and Hiromitsu Takizawa : 高齢乳癌患者におけるCDK4/6阻害剤投与の検討, 第31回日本乳癌学会学術総会, Jun. 2023.
21.	Sawaka Yukishige, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroyuki Morino, 吉田友紀子, 宮本容子 and Hiromitsu Takizawa : BRCA遺伝学的検査の結果inconclusiveとなった3例, 第29回日本遺伝性腫瘍学会学術集会, Jun. 2023.
22.	Shin-ichi Sakamoto, Mariko Aoyama, 井﨑富由実, Taihei Takeuchi, Hiroyuki Sumitomo, Naoki Miyamoto, Seiya Inoue, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : レンバチニブ投与により難治性気胸を発症した甲状腺未分化癌の一例, 第35回日本内分泌外科学会総会, Jun. 2023.
23.	井﨑富由実, Mariko Aoyama, Taihei Takeuchi, Hiroyuki Sumitomo, Naoki Miyamoto, Shin-ichi Sakamoto, Satoshi Fujiwara, Seiya Inoue, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 排便時の怒責が誘因となった甲状腺被膜出血の1例, 第35回日本内分泌外科学会総会, Jun. 2023.
24.	Mariko Aoyama, 井﨑富由実, Tomohiro Inui, Shin-ichi Sakamoto, Naoki Miyamoto, Seiya Inoue, Naoya Kawakita, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : VANS甲状腺悪性腫瘍手術の手術成績, 第35回日本内分泌外科学会総会, Jun. 2023.
25.	Seiya Inoue, Masakazu Goto, Satoshi Fujiwara, 井﨑富由実, Taihei Takeuchi, Hiroyuki Sumitomo, Naoki Miyamoto, Shin-ichi Sakamoto, Mariko Aoyama, Mika Takashima, Naoya Kawakita, Hiroaki Toba, Hiromitsu Takizawa and Yoshihiro Tsuruo : 縦隔鏡下食道切除術における開胸手技習得のわれわれの取り組み, 第123回日本外科学会定期学術集会, Apr. 2023.
26.	Hiroaki Inoue, Souichiro Sasa, Tomohiro Inui, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Yoshimi Bando and Hiromitsu Takizawa : 針生検における非浸潤癌周囲のTILsは浸潤癌の存在を予測できるか, 第123回日本外科学会定期学術集会, Apr. 2023.
27.	Naoya Kawakita, Hiroaki Toba, Shin-ichi Sakamoto, 井﨑富由実, Taihei Takeuchi, Hiroyuki Sumitomo, Naoki Miyamoto, Mariko Aoyama, Mika Takashima, Daisuke Matsumoto, Seiya Inoue, Yukikiyo Kawakami, Kazuya Kondo and Hiromitsu Takizawa : マウスiPS細胞由来の気管支肺胞幹細胞を用いた気道上皮再生, 第123回日本外科学会定期学術集会, Apr. 2023.
28.	Hiroyuki Sumitomo, Hiroaki Toba, 井﨑富由実, Taihei Takeuchi, Tomohiro Inui, Shin-ichi Sakamoto, Naoki Miyamoto, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Mika Takashima, Seiya Inoue, Naoya Kawakita, Satoshi Fujiwara, Masakazu Goto, Kazumasa Okumura, Yukikiyo Kawakami and Hiromitsu Takizawa : 大きな縦隔腫瘍に対する気縦隔を用いた縦隔鏡アプローチの有用性, 第123回日本外科学会定期学術集会, Apr. 2023.
29.	Naoki Miyamoto, Kazuya Kondo, 井﨑富由実, 竹内大平, 住友弘幸, Shin-ichi Sakamoto, Mariko Aoyama, Mika Takashima, Naoya Kawakita, Yukikiyo Kawakami, Hiroaki Toba and Hiromitsu Takizawa : A case of edema and weight gain as irAE after nivolumab administration, 第20回日本臨床腫瘍学会学術集会, Mar. 2023.
30.	井﨑富由実, Mariko Aoyama, 竹内大平, Hiroyuki Sumitomo, Naoki Miyamoto, Shin-ichi Sakamoto, Satoshi Fujiwara, Seiya Inoue, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 抗血栓薬内服中に甲状腺被膜出血をきたし緊急手術を要した1例, 第51回中国四国甲状腺外科研究会, Feb. 2023.
31.	Shin-ichi Sakamoto, Mariko Aoyama, Tomohiro Inui, Naoki Miyamoto, Seiya Inoue, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : Weekly paclitaxelと放射線外照射を併用した甲状腺未分化癌の一例, 第51回中国四国甲状腺外科研究会, Feb. 2023.
32.	Mariko Aoyama, 井﨑富由実, 竹内大平, Shin-ichi Sakamoto, Naoki Miyamoto, Seiya Inoue, Naoya Kawakita, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 分子標的治療薬の手術前使用の経験, 第51回中国四国甲状腺外科研究会, Feb. 2023.
33.	Souichiro Sasa, Hiroaki Inoue, INUI Tomohiro, Naoki Miyamoto, Mariko Aoyama, Kazumasa Okumura, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 原因不明の発熱により治療方針決定に難渋した局所進行乳癌の一例, 第32回日本乳癌検診学会学術総会, Nov. 2022.
34.	Hiroaki Inoue, Souichiro Sasa, Tomohiro Inui, Mariko Aoyama, Kazumasa Okumura, Hiroyuki Sumitomo, Naoki Miyamoto, Hiroaki Toba, Yuka Hiroshima and Hiromitsu Takizawa : 当院におけるトモシンセシスガイド下マンモトーム生検の経験, 第32回日本乳癌検診学会学術総会, Nov. 2022.
35.	Souichiro Sasa, Hiroaki Inoue, Tomohiro Inui, Mariko Aoyama, Kazumasa Okumura, 板東真由, Ichiro Hashimoto, Atsuko Yoshida, 山口美代子, Hiroaki Toba, Masakazu Goto and Hiromitsu Takizawa : 多診療科・多職種チーム連携が有用であった妊娠期乳癌の1例, 第10回日本乳房オンコプラスティックサージャリー学会総会, Oct. 2022.
36.	Satoshi Fujiwara, Takahiro Yoshida, Masakazu Goto, Seiya Inoue, INUI Tomohiro, Shin-ichi Sakamoto, Naoki Miyamoto, Mariko Aoyama, Hiroaki Toba and Hiromitsu Takizawa : 同時性肺腫瘍を伴う進行食道癌に対し，一期的手術を施行した3例の検討, 第76回日本食道学会学術集会, Sep. 2022.
37.	Seiya Inoue, Takahiro Yoshida, Masakazu Goto, Satoshi Fujiwara, INUI Tomohiro, Shin-ichi Sakamoto, Naoki Miyamoto, Mariko Aoyama, Hiroaki Toba and Hiromitsu Takizawa : 食道切除後の最適な胃管再建法, 第76回日本食道学会学術集会, Sep. 2022.
38.	Seiya Inoue, Masakazu Goto, Satoshi Fujiwara, Hiroyuki Sumitomo, 井﨑富由実, 竹内大平, Tomohiro Inui, Shin-ichi Sakamoto, Naoki Miyamoto, Mariko Aoyama, Hiroaki Toba and Hiromitsu Takizawa : 食道胃管吻合におけるわれわれの取り組み, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
39.	Hiroaki Inoue, INUI Tomohiro, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 骨髄癌症，硬膜下血腫によりoncological emergencyの状態であったが救命し得た乳癌多発骨転移の1例, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
40.	Mariko Aoyama, Shin-ichi Sakamoto, INUI Tomohiro, Naoki Miyamoto, Seiya Inoue, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : Weekly pacltaxelと放射線外照射が有効であった甲状腺未分化癌の1例, 第97回中国四国外科学会総会/第27回中国四国内視鏡外科研究会, Sep. 2022.
41.	Seiya Inoue, Takahiro Yoshida, Masakazu Goto, Satoshi Fujiwara, INUI Tomohiro, Shin-ichi Sakamoto, Naoki Miyamoto, Mariko Aoyama, Hiroaki Toba and Hiromitsu Takizawa : 食道切除後再建術における取り組み-ICG血流評価法とCollard変法の有用性-, 第77回日本消化器外科学会総会, Jul. 2022.
42.	Mariko Aoyama, Hiroaki Inoue, INUI Tomohiro, Souichiro Sasa, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida and Hiromitsu Takizawa : 3次治療でオラパリブが著効したBRCA陽性転移再発乳癌の1例, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
43.	Kazumasa Okumura, INUI Tomohiro, Souichiro Sasa, Mariko Aoyama, Hiroaki Inoue, Hiroaki Toba, Takahiro Yoshida, Hiromitsu Takizawa and Akira Tangoku : ペムブロリズムマブの免疫関連副作用と考えられた甲状腺中毒，DICを発症しステロイドが著効した1例, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
44.	INUI Tomohiro, Hiroaki Inoue, Souichiro Sasa, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Hiromitsu Takizawa and Akira Tangoku : 薬剤性肝障害を来したがCDK4/6阻害薬を変更し治療継続し得た2例, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
45.	Souichiro Sasa, Hiroaki Inoue, INUI Tomohiro, Naoki Miyamoto, Mariko Aoyama, Kazumasa Okumura, Takahiro Yoshida, Hiroaki Toba and Hiromitsu Takizawa : 当院におけるコンパニオン診断目的に行われたBRCA1/2遺伝学的検査の現状とオラパリブの使用経験, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
46.	Hiroaki Inoue, 山下華乃, Souichiro Sasa, INUI Tomohiro, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Takahiro Yoshida, Yoshimi Bando, Hiromitsu Takizawa and Akira Tangoku : 非浸潤癌におけるTILsは浸潤の有無を予測できるか, 第30回日本乳癌学会学術総会(ハイブリッド開催), Jun. 2022.
47.	Mariko Aoyama, INUI Tomohiro, Shin-ichi Sakamoto, Naoki Miyamoto, Seiya Inoue, Naoya Kawakita, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 肺転移と腎転移をきたした甲状腺乳頭癌の1症例, 第34回日本内分泌外科学会総会(ハイブリッド開催), Jun. 2022.
48.	Seiya Inoue, Takahiro Yoshida, Masakazu Goto, Satoshi Fujiwara, Mariko Aoyama, Naoya Kawakita, Hiroaki Toba, Hiromitsu Takizawa, 橋本脩平 and Yasuhiro Hamada : 食道癌根治術における術前GLIM criteriaを用いた術後成績の予測, 第122回日本外科学会定期学術集会(ハイブリッド開催), Apr. 2022.
49.	Hiroaki Inoue, Souichiro Sasa, INUI Tomohiro, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Takahiro Yoshida and Hiromitsu Takizawa : エリブリン投与中の末梢血総リンパ球数変化率は進行・再発乳癌の予後予測因子となるか, 第122回日本外科学会定期学術集会(ハイブリッド開催), Apr. 2022.
50.	Soichiroh Sasa, Hiroaki Inoue, Tomohiro INUI, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida, Akira Tangoku, 高橋雅子 and 笹三徳 : 乳腺後隙に発生した急速増大を伴う嚢胞性腫瘤の一切除例, 第31回日本乳癌検診学会学術総会(ハイブリッド開催), Nov. 2021.
51.	Hiroaki Inoue, Soichiroh Sasa, Tomohiro INUI, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida, Hiromitsu Takizawa and Akira Tangoku : 当院におけるAYA世代乳癌患者の発見契機と予後について, 第31回日本乳癌検診学会学術総会(ハイブリッド開催), Nov. 2021.
52.	Mariko Aoyama, Tomohiro INUI, 坂本晋一, 宮本直輝, Seiya Inoue and Hiromitsu Takizawa : EMG気管チューブの声帯圧迫によって両側声帯神経麻痺を来したと考えられる2例, 第54回日本内分泌外科学会学術大会(WEB開催), Oct. 2021.
53.	Hidenori Maki, Seiya Inoue, 南城和正, Mariko Aoyama, Masakazu Goto, Takeshi Nishino, Takahiro Yoshida, Hiromitsu Takizawa and Akira Tangoku : 巨大食道裂孔ヘルニアを伴う特発性食道破裂の一例, 第75回日本食道学会学術集会(ハイブリッド開催), Sep. 2021.
54.	南城和正, Seiya Inoue, Hidenori Maki, 庄野隆志, Mariko Aoyama, Takeshi Nishino, Masakazu Goto, Takahiro Yoshida, Hiromitsu Takizawa and Akira Tangoku : 食道癌術後に門脈ガス血症・腸管気腫症を発症した1例, 第75回日本食道学会学術集会(ハイブリッド開催), Sep. 2021.
55.	庄野隆志, Seiya Inoue, 南城和正, Yasuyo Saijo, Hidenori Maki, Mariko Aoyama, Takeshi Nishino, Masakazu Goto, Takahiro Yoshida, Hiromitsu Takizawa and Akira Tangoku : 術前化学療法に効果を示し，根治手術を施行した進行食道粘表皮癌の1例, 第75回日本食道学会学術集会(ハイブリッド開催), Sep. 2021.
56.	Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, 庄野隆志, 南城和正, Hidenori Maki, Mariko Aoyama, Akira Tangoku, 橋本脩平 and Yasuhiro Hamada : 当院の食道癌集学的チーム医療の現状と栄養評価, 第75回日本食道学会学術集会(ハイブリッド開催), Sep. 2021.
57.	乾友浩, Hiroaki Inoue, Soichiroh Sasa, Mariko Aoyama, Kazumasa Okumura, 宮本直輝, Hiroaki Toba, Takahiro Yoshida and Hiromitsu Takizawa : アベマシクリブ投与中に重篤な間質性肺炎を来したが救命しえた1例, 第18回日本乳癌学会中国四国地方会(WEB開催), Sep. 2021.
58.	Kazumasa Okumura, INUI Tomohiro, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Hiroaki Toba and Akira Tangoku : 術後補助療法としてのTC療法の治療成績の検討, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
59.	Soichiroh Sasa, INUI Tomohiro, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura, Hiroaki Toba and Akira Tangoku : 乳癌術前化学療法におけるアルブミン懸濁型パクリタキセルの使用経験, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
60.	Mariko Aoyama, Hiroaki Inoue, INUI Tomohiro, Soichiroh Sasa, Kazumasa Okumura, Hiroaki Toba, Yoshimi Bando and Akira Tangoku : 浸潤性小葉癌の病変の広がり診断についての検討-画像所見と病理学的所見との相関に注目して-, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
61.	Hiroaki Inoue, Soichiroh Sasa, Mariko Aoyama, Tomohiro Inui, Kazumasa Okumura, Hiroaki Toba, Naoki Miyamoto and Akira Tangoku : 高齢乳癌患者におけるCARGスコアは予後予測因子になるか?, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
62.	INUI Tomohiro, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura, Hiroaki Toba and Akira Tangoku : 当院における乳癌脳転移症例の検討, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
63.	山尾雅美, 山口夏美, 松本麻依, 平田有紀奈, 西尾進, Tomohiro Inui, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura, Hiroaki Toba, Takeshi Oya, Yoshimi Bando, Masataka Sata and Akira Tangoku : 硬化性腺症を背景に発生した悪性葉状腫瘍の1例, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
64.	Hiroaki Toba, INUI Tomohiro, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura and Akira Tangoku : かかりつけ医と役割分担してより良い乳癌診療をするための包括的な取り組み, 第29回日本乳癌学会学術総会(ハイブリッド開催), Jul. 2021.
65.	庄野隆志, Mariko Aoyama, 南城和正, 山本清成, Hidenori Maki, Tomohiro Inui, Shinichi Sakamoto, Tomoko Kobayashi, Shingen Nakamura, Hiromitsu Takizawa and Akira Tangoku : アブスコパル効果を示した甲状腺原発形質細胞腫の1例, 第33回日本内分泌外科学会総会, Jun. 2021.
66.	山本清成, Mariko Aoyama, Hiromitsu Takizawa, 南城和正, 庄野隆志, Hidenori Maki, Tomohiro Inui, Shinichi Sakamoto and Akira Tangoku : 右心房転移をきたした甲状腺未分化癌の1例, 第33回日本内分泌外科学会総会, Jun. 2021.
67.	Shinichi Sakamoto, Mariko Aoyama, Hiromitsu Takizawa, 庄野隆志, 山本清成 and Akira Tangoku : 低用量レンバチニブ投与で病勢コントロールを得た甲状腺乳頭癌の3例, 第33回日本内分泌外科学会総会, Jun. 2021.
68.	Mariko Aoyama, Hiromitsu Takizawa, 庄野隆志, 山本清成, Tomohiro Inui, Shinichi Sakamoto and Akira Tangoku : 原発性副甲状腺機能亢進症術後のテタニー発症の術前因子についての検討, 第33回日本内分泌外科学会総会, Jun. 2021.
69.	Hiromitsu Takizawa, Mariko Aoyama, 庄野隆志, 南城和正, 山本清成, Tomohiro Inui, Shinichi Sakamoto and Akira Tangoku : レンバチニブが甲状腺乳頭癌多発肺転移と腎細胞癌に有効であった1例, 第33回日本内分泌外科学会総会, Jun. 2021.
70.	Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Kai Mizobuchi, 竹原恵美, Mariko Aoyama, Masami Morimoto and Akira Tangoku : 当科における縦隔鏡下食道切除術の安全性に関する検討, 第33回日本内視鏡外科学会総会(ハイブリッド開催), Mar. 2021.
71.	Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Kai Mizobuchi, 鈴木恵美, Mariko Aoyama, Masami Morimoto and Akira Tangoku : 縫合不全回避のためのわれわれの工夫, 第74回日本食道学会学術集会(ハイブリッド型開催), Dec. 2020.
72.	Soichiroh Sasa, Hiroaki Inoue, Kazumasa Okumura, Mariko Aoyama, INUI Tomohiro, Hiroaki Toba and Akira Tangoku : 当施設におけるステレオガイド下マンモトーム生検の検討, 第30回日本乳癌検診学会学術総会(ハイブリッド形式), Nov. 2020.
73.	INUI Tomohiro, Hiroaki Inoue, Soichiroh Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida, Yoshimi Bando and Akira Tangoku : 精査機関である当院における針生検の現状, 第30回日本乳癌検診学会学術総会(ハイブリッド形式), Nov. 2020.
74.	Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Mariko Aoyama, Naoya Kawakita, Hiromitsu Takizawa and Akira Tangoku : 生検組織を用いた食道扁平上皮癌に対する初回化学療法の効果と予後予測因子の解明, 第73回日本胸部外科学会定期学術集会(Web開催), Oct. 2020.
75.	Takahiro Yoshida, Takeshi Nishino, Seiya Inoue, Masakazu Goto, Akira Tangoku, Yoshihiro Tsuruo, Mariko Aoyama, Hiroaki Toba and Hiromitsu Takizawa : 食道外科手術におけるカダバートレーニングの経験と展望, 第73回日本胸部外科学会定期学術集会(Web開催), Oct. 2020.
76.	庄野隆志, Takeshi Nishino, 南城和正, 山本清成, 牧秀則, INUI Tomohiro, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Seiya Inoue, Masakazu Goto, Kazumasa Okumura, Takahiro Yoshida and Akira Tangoku : 乳癌術後20年目に食道転移をきたした1例, 第82回日本臨床外科学会総会, Oct. 2020.
77.	庄野隆志, Hiroaki Inoue, 山本清成, Tomohiro Inui, Naoki Miyamoto, Soichiroh Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Takahiro Yoshida and Akira Tangoku : 腹膜播種によるイレウスに対しベバシズマブ+パクリタキセル療法が著効した再発乳癌の1例, 第17回日本乳癌学会中国四国地方会(Web開催), Oct. 2020.
78.	Naoki Miyamoto, Hiroaki Inoue, Soichiroh Sasa, Hiroaki Toba, Masami Morimoto, Hirokazu Takechi, Mariko Aoyama, 竹原恵美, Kai Mizobuchi and Akira Tangoku : HER2陽性乳癌患者における末梢血リンパ球数，好中球リンパ球比についての検討, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
79.	Hiroaki Inoue, Soichiroh Sasa, Hiroaki Toba, Masami Morimoto, Hirokazu Takechi, Mariko Aoyama, Naoki Miyamoto, 竹原恵美, Kai Mizobuchi and Akira Tangoku : CARGスコアは高齢者乳癌患者の薬物療法決定に際し有用か?, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
80.	Hirokazu Takechi, 松岡由江, 一宮由貴, 三木幸代, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Masami Morimoto, Hiroaki Toba, Takahiro Yoshida and Akira Tangoku : 乳房再建により急速に鬱症状が改善した1例, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
81.	Masami Morimoto, 宮本容子, 吉田友紀子, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Hiroaki Toba, Hirokazu Takechi and Akira Tangoku : 臨床遺伝診療部の従事者間で治療方針を決定したBRCAバリアントの1症例, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
82.	竹原恵美, Hiroaki Inoue, Soichiroh Sasa, Masami Morimoto, Hirokazu Takechi, Hiroaki Toba, Mariko Aoyama, Naoki Miyamoto, Kai Mizobuchi and Akira Tangoku : 当院における葉状腫瘍の経験とフォローアップの重要性, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
83.	山口美代子, 松岡由江, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Masami Morimoto, Hirokazu Takechi and Akira Tangoku : 乳癌患者に対する多職種カンファレンスの充実に向けた取り組み, 第28回日本乳癌学会学術総会(Web開催), Oct. 2020.
84.	Mariko Aoyama, Hiromitsu Takizawa, Mitsuhiro Tsuboi and Akira Tangoku : 甲状腺未分化癌同所移植マウスモデルと小動物用FDG-PET/CTを用いた分子標的治療効果判定法の確立, 第24回日本がん分子標的治療学会学術集会(ハイブリッド形式), Oct. 2020.
85.	Mariko Aoyama, Hiromitsu Takizawa, Kai Mizobuchi, 竹原恵美, Naoki Miyamoto, Mitsuhiro Tsuboi and Akira Tangoku : 自家蛍光による副甲状腺の同定-励起光による自家蛍光の変化に注目して-, 第32回日本内分泌外科学会総会, Sep. 2020.
86.	Mariko Aoyama, Hiromitsu Takizawa, Seiya Inoue, Naoya Kawakita, Mitsuhiro Tsuboi, Kazuya Kondo and Akira Tangoku : 小動物用FDG-PET/CTを使用した甲状腺未分化癌の同所移植マウスモデルの作成, 第120回日本外科学会定期学術集会(Web開催), Aug. 2020.

Et cetera, Workshop:

1.	Masakazu Goto, Seiya Inoue, Satoshi Fujiwara, 髙杉遥, 細川暉雄, Sawaka Yukishige, Taihei Takeuchi, Tomohiro Inui, Hiroyuki Sumitomo, Naoki Miyamoto, Shin-ichi Sakamoto, Souichiro Sasa, Atsushi Morishita, Mariko Aoyama, Hiroaki Inoue, Naoya Kawakita, Hiroaki Toba and Hiromitsu Takizawa : 当院における腹臥位胸腔鏡下食道亜全摘術の術後短期成績について, 第36回四国内視鏡外科研究会, Mar. 2024.
2.	Masakazu Goto, Seiya Inoue, Satoshi Fujiwara, 髙杉遥, 細川暉雄, 竹内大平, Hiroyuki Sumitomo, Atsushi Morishita, Mariko Aoyama, Hiroaki Toba and Hiromitsu Takizawa : 腹臥位胸腔鏡下食道亜全摘術の術後短期成績について, 第44回四国食道疾患研究会学術講演会, Feb. 2024.
3.	Satoshi Fujiwara, Masakazu Goto, Seiya Inoue, 髙杉遥, 細川暉雄, 竹内大平, Hiroyuki Sumitomo, Atsushi Morishita, Mariko Aoyama, Hiroaki Toba and Hiromitsu Takizawa : 食道癌根治術後の再発症例の検討, 第44回四国食道疾患研究会学術講演会, Feb. 2024.
4.	Seiya Inoue, Masakazu Goto, Satoshi Fujiwara, 髙杉遥, 細川暉雄, 竹内大平, Hiroyuki Sumitomo, Atsushi Morishita, Mariko Aoyama, Hiroaki Toba and Hiromitsu Takizawa : 吻合部トラブル回避のわれわれの工夫 ∼吻合法の比較検討∼, 第44回四国食道疾患研究会学術講演会, Feb. 2024.
5.	髙杉遥, Masakazu Goto, Seiya Inoue, Satoshi Fujiwara, 細川暉雄, 竹内大平, Hiroyuki Sumitomo, Atsushi Morishita, Mariko Aoyama, Hiroaki Toba and Hiromitsu Takizawa : 食道胃接合部癌における術式別短期成績の比較, 第44回四国食道疾患研究会学術講演会, Feb. 2024.
6.	細川暉雄, Mariko Aoyama, 竹内大平, Tomohiro Inui, 髙杉遥, Shin-ichi Sakamoto, Hiroyuki Sumitomo, Naoki Miyamoto, Atsushi Morishita, Seiya Inoue, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : レンバチニブ内服中に間質性肺炎をきたした甲状腺低分化癌の一例, 第52回中国四国甲状腺外科研究会, Feb. 2024.
7.	Shin-ichi Sakamoto, Mariko Aoyama, 細川暉雄, 竹内大平, 髙杉遥, Naoki Miyamoto, Atsushi Morishita, Seiya Inoue, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : Dynamic CTが局在診断に有用であった原発性副甲状腺機能亢進症の2例, 第52回中国四国甲状腺外科研究会, Feb. 2024.
8.	Mariko Aoyama, 細川暉雄, 竹内大平, 髙杉遥, Shin-ichi Sakamoto, Naoki Miyamoto, Atsushi Morishita, Seiya Inoue, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba, Yoshimi Bando, Hisanori Uehara and Hiromitsu Takizawa : 穿刺吸引細胞への免疫染色併用が術前診断に有用であった2症例, 第52回中国四国甲状腺外科研究会, Feb. 2024.
9.	Mariko Aoyama : 甲状腺がん, 徳島大学病院がん診療連携センターフォーラム2024, Jan. 2024.
10.	井﨑富由実, Hiroaki Inoue, Tomohiro Inui, Souichiro Sasa, Mariko Aoyama, Naoki Miyamoto, Kazumasa Okumura, Hiroaki Toba, Masakazu Goto, 住田智志, Yoshimi Bando and Hiromitsu Takizawa : 巨大石灰化を認めた骨・軟骨化生を伴う乳癌の1例, 第19回日本乳癌学会中国四国地方会, Sep. 2022.
11.	青山理央, Souichiro Sasa, Tomohiro Inui, Mariko Aoyama, Kazumasa Okumura, Hiroaki Inoue, Hiroaki Toba, Masakazu Goto, Takeshi Oya and Hiromitsu Takizawa : 乳腺腺様嚢胞癌の一例, 第19回日本乳癌学会中国四国地方会, Sep. 2022.
12.	Mariko Aoyama, Tomohiro Inui, Shinichi Sakamoto, Naoki Miyamoto, Seiya Inoue, Naoya Kawakita, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 当院でのBasedow病に対する内視鏡下甲状腺手術についての治療成績, 第5回徳島外科医会, Feb. 2022.
13.	Tomohiro Inui, Hiroaki Inoue, Soichiroh Sasa, Mariko Aoyama, Kazumasa Okumura, Naoki Miyamoto, Hiroaki Toba, Takahiro Yoshida and Hiromitsu Takizawa : アベマシクリブ投与中に重篤な間質性肺炎を来したが救命しえた1例, 第5回徳島外科医会, Feb. 2022.
14.	Seiya Inoue, Takahiro Yoshida, Masakazu Goto, Satoshi Fujiwara, Tomohiro Inui, Shinichi Sakamoto, Naoki Miyamoto, Mariko Aoyama, Hiroaki Toba, Akira Tangoku and Hiromitsu Takizawa : 安全な食道再建のわれわれの工夫, 第5回徳島外科医会, Feb. 2022.
15.	Seiya Inoue, Takahiro Yoshida, Masakazu Goto, Satoshi Fujiwara, Tomohiro Inui, Shinichi Sakamoto, Naoki Miyamoto, Mariko Aoyama, Akira Tangoku, Hiroaki Toba and Hiromitsu Takizawa : 食道切除後再建術における最近の取り組み-ICG血流評価法とCollard変法の有用性-, 第42回四国食道疾患研究会(WEB開催), Feb. 2022.
16.	Satoshi Fujiwara, Takahiro Yoshida, Masakazu Goto, Seiya Inoue, Tomohiro Inui, Shinichi Sakamoto, Naoki Miyamoto, Mariko Aoyama, Akira Tangoku, Hiroaki Toba and Hiromitsu Takizawa : 肺癌を合併した食道癌に対し，一期的手術を施行した3例の検討, 第42回四国食道疾患研究会(WEB開催), Feb. 2022.
17.	Mariko Aoyama, Tomohiro Inui, Shinichi Sakamoto, Naoki Miyamoto, Seiya Inoue, Naoya Kawakita, Satoshi Fujiwara, Masakazu Goto, Hiroaki Toba and Hiromitsu Takizawa : 当院でのBasedow病に対する内視鏡下甲状腺手術についての治療成績, 第50回中国四国甲状腺外科研究会, Feb. 2022.
18.	庄野隆志, Mariko Aoyama, 南城和正, 山本清成, Hidenori Maki, Tomohiro Inui, Shinichi Sakamoto, Tomoko Kobayashi, Shingen Nakamura, Hiromitsu Takizawa and Akira Tangoku : アブスコパル効果を示した甲状腺原発形質細胞腫の1例, 第49回中国四国甲状腺外科研究会(ハイブリッド開催), Feb. 2021.
19.	Mariko Aoyama, Hiromitsu Takizawa, 庄野隆志, 南城和正, Hidenori Maki, 山本清成, INUI Tomohiro, Naoki Miyamoto, Shinichi Sakamoto and Akira Tangoku : 低用量レンバチニブで長期PRを維持できている再発甲状腺乳頭癌の1例, 第49回中国四国甲状腺外科研究会(ハイブリッド開催), Feb. 2021.
20.	INUI Tomohiro, Hiroaki Inoue, Soichiroh Sasa, Mariko Aoyama, Kazumasa Okumura, Hiroaki Toba, Hiromitsu Takizawa and Akira Tangoku : トラスツズマブ+ペルツズマブ投与にて重度のinfusion reactionを認めたが再投与可能であった1例, 第4回徳島外科医会, Feb. 2021.
21.	Soichiroh Sasa, Hiroaki Inoue, Kazumasa Okumura, Mariko Aoyama, INUI Tomohiro, Hiroaki Toba and Akira Tangoku : 当施設におけるステレオガイド下マンモトーム生検の検討, 第4回徳島外科医会, Feb. 2021.
22.	山本清成, Mariko Aoyama, Hiromitsu Takizawa, 南城和正, 庄野隆志, Hidenori Maki and Akira Tangoku : 右心房転移をきたした甲状腺未分化癌の1例, 第4回徳島外科医会, Feb. 2021.
23.	庄野隆志, Takeshi Nishino, 南城和正, 山本清成, Hidenori Maki, Tomohiro Inui, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Seiya Inoue, Masakazu Goto, Kazumasa Okumura, Takahiro Yoshida and Akira Tangoku : 乳癌術後20年目に食道転移をきたした1例, 第261回徳島医学会学術集会(Web配信), Aug. 2020.
24.	Tomohiro Inui, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Kazumasa Okumura and Akira Tangoku : 乳癌に対するCNB後にNeedle tract seedingを認めた1例, 第261回徳島医学会学術集会(Web配信), Aug. 2020.
25.	Hiroaki Toba, Hiromitsu Takizawa, 庄野隆志, 南城和正, 山本清成, Hidenori Maki, Tomohiro Inui, Shinichi Sakamoto, Naoki Miyamoto, Soichiroh Sasa, Mariko Aoyama, Hiroaki Inoue, Mika Takashima, Daisuke Matsumoto, Seiya Inoue, Naoya Kawakita, Masakazu Goto, Takeshi Nishino, Kazumasa Okumura, Takahiro Yoshida, Yukikiyo Kawakami, Mitsuteru Yoshida, Kazuya Kondo and Akira Tangoku : より良いがんの地域連携体制構築のための取り組み, 第261回徳島医学会学術集会(Web配信), Aug. 2020.

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)

LEDを使用した副甲状腺自家蛍光イメージング機器の開発 (Project/Area Number: 24K19335 )
副甲状腺自家蛍光イメージング機器の開発 (Project/Area Number: 21K16380 )
Search by Researcher Number (60598639)

Assistant Professor : Aoyama, Mariko

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

Proceeding of International Conference:

Proceeding of Domestic Conference:

Et cetera, Workshop:

Grants-in-Aid for Scientific Research (KAKEN Grants Database @ NII.ac.jp)